Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Applied BioCodeTPE:6598 +0.92%77 3-Year EBITDA Growth Rate is 1.30% as of Jun. 2026, which is 65% below its 10-year median of 3.70. GuruFocus rates TPE:6598 with a GF Score™ of 77/100 and a GF Value™ of NT$31.96 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Applied BioCode ranks worse than 62.79% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 1.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Applied BioCode was 48.90% per year. The lowest was -21.20% per year. And the median was 3.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Applied BioCode 3-Year EBITDA Growth Rate Related Terms
TPE:6598 vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Applied BioCode's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Applied BioCode's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 1.30% mean?
Applied BioCode (TPE:6598) has a 3-Year EBITDA Growth Rate of 1.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Applied BioCode and its competitors. This is 65% below median its historical median of 3.70. According to the industry distribution chart, Applied BioCode ranks #432 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 62.8%.
Is Applied BioCode's 3-Year EBITDA Growth Rate too high?
Applied BioCode's current 3-Year EBITDA Growth Rate of 1.30% is 65% below median its 10-year median of 3.70. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Applied BioCode's value of 1.30% is 84% below this industry median. Based on the distribution chart, Applied BioCode ranks #432 out of 688 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Applied BioCode has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #432 out of 688 companies for 3-Year EBITDA Growth Rate. This places Applied BioCode in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Applied BioCode's value of 1.30% is 84% below this benchmark. While the company's 10-year median is 3.70 vs. the industry median of 8.10, Applied BioCode has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Applied BioCode's current 3-Year EBITDA Growth Rate of 1.30% is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current 3-Year EBITDA Growth Rate is 1.30%, which is 65% below median its own 10-year median of 3.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$31.96, compared to a current price of NT$27.40 — trading 14.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 1.30%, which is 65% below median its 10-year median of 3.70 and 84% below the Medical Devices & Instruments industry median of 8.10. Applied BioCode's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current 3-Year EBITDA Growth Rate is 1.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$27.40 is trading 14.3% below its estimated GF Value™ of NT$31.96.
GuruFocus considers Applied BioCode to be Modestly Undervalued.
Key valuation signals for TPE:6598:
3-Year EBITDA Growth Rate: 1.30% (65% below median its 10-year median of 3.70)
GF Value™: NT$31.96 vs. price of NT$27.40 (14.3% below fair value)
Industry Position: 84% below the Medical Devices & Instruments median (#432 of 688)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
77GF Score
Get the complete analysis for TPE:6598
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
